NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 241 filers reported holding NOVOCURE LTD in Q3 2019. The put-call ratio across all filers is 0.53 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $477,000 | +31.0% | 6,284 | +42.9% | 0.04% | +63.0% |
| Q1 2022 | $364,000 | +0.8% | 4,399 | -8.5% | 0.03% | -27.0% |
| Q4 2021 | $361,000 | -72.2% | 4,808 | -17.8% | 0.04% | -70.6% |
| Q2 2021 | $1,297,000 | +197.5% | 5,846 | +77.2% | 0.13% | +306.5% |
| Q1 2021 | $436,000 | -21.9% | 3,299 | -34.2% | 0.03% | -67.7% |
| Q3 2020 | $558,000 | -56.4% | 5,013 | -75.2% | 0.10% | +28.0% |
| Q2 2019 | $1,280,000 | – | 20,245 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |